CUCO-UV: Effectiveness of a Hydrophobic Dressing for Microorganisms' Colonization and Infection Control of Vascular Ulcers

Sponsor
University of Malaga (Other)
Overall Status
Unknown status
CT.gov ID
NCT03667937
Collaborator
BSN Medical GmbH (Industry), Andalusian Health Service (Other)
204
1
2
23.5
8.7

Study Details

Study Description

Brief Summary

This study will determine the effectiveness of CUTIMED® hydrophobic dressings against AQUACEL® silver dressings in bacterial colonization of vascular ulcers.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: CUTIMED
  • Other: AQUACEL silver
Phase 4

Detailed Description

Chronic wounds with torpid evolution are a real challenge for health services today. In the case of venous ulcers, it is estimated that more than 80% of these wounds may be colonized or infected by bacteria, which is associated with its chronification by delaying the healing process.

The most widespread therapeutic strategy in routine clinical practice is the use of silver dressings, due to its high antimicrobial power, although the effectiveness of these in venous ulcers is not supported by solid evidence. In addition, there are some uncertainties about the possible adverse effects of systemic absorption of silver molecules, as well as bacterial resistance to silver and the high cost associated with prolonged treatments.

In this sense, a novel method to deal with this problem is the use of dressings with high hydrophobic power, such as CUTIMED®.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
204 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effectiveness of a Hydrophobic Dressing for Microorganisms' Colonization and Infection Control of Vascular Ulcers: An Open, Controlled, Randomized Study, With Blinded Endpoint (PROBE Trial): CUCO-UV Study
Actual Study Start Date :
May 15, 2019
Anticipated Primary Completion Date :
Dec 30, 2020
Anticipated Study Completion Date :
Apr 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: CUTIMED

After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply the CUTIMED dressing. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage. If the wound exudate decreases, or the removal of the dressing is difficult, it will be changed to CUTIMED gel; in case of abundant exudate, the use of alginate without silver will be allowed for the treatment, because it is neutral with the bacterial load, placed on the CUTIMED dressing. Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks).

Combination Product: CUTIMED
Hydrophobic Dressing

Active Comparator: AQUACEL silver

After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply Aquacel-Ag. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage. Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks).

Other: AQUACEL silver
Silver Dressing

Outcome Measures

Primary Outcome Measures

  1. Microorganisms' Colonization Level [Change from baseline, at 4, 8 and 12 weeks]

    Evaluated by Reverse Transcription Polymerase Chain Reaction (RT-PCR) identification technique and quantified in colony forming units (CFU) and in ng of bacterial DNA per μL of vascular ulcer exudate.

Secondary Outcome Measures

  1. Pain due to the wound [Change from baseline at 4, 8 and 12 weeks]

    Measured with tha Visual Analogue Scale (VAS): Minimum score=1; Maximum score=10.

  2. Wound size (wound reduction percentage) [Baseline, 4, 8 and 12 weeks]

    It will be evaluated by planimetry with PictZar 7.5 software

  3. Healing time [Change from baseline at 4, 8 and 12 weeks]

    This outcome will be measure by number of days until healing

  4. Complete wound healing (Resvech 2.0 score) [Change from baseline at 4, 8 and 12 weeks]

    Complete healing will be considered with a 0 score in the fourth dimension of the Resvech 2.0 scale

  5. Patient quality of life [Change from baseline at 12 weeks]

    Measured with Charing Cross Venous Ulcer Questionnaire (CCVUQ), in its Spanish version. The CCVUQ is composed of 22 items that determine four important dimensions for health: the social function, domestic activities, the aesthetic dimension and the emotional state. Each item should be assessed using a Likert scale with a punctuation from 1 to 5. In their interpretation, lower scores indicate a better quality of life.

  6. Adverse Events [Change from baseline at 4, 8 and 12 weeks]

    Adverse events related with the treatment, referred by patients, caregivers or health professionals

Other Outcome Measures

  1. Wound healing evolution [Baseline, 4, 8 and 12 weeks]

    Measured with "Resultados esperados de la valoración y evolución de la cicatrización de las heridas crónicas" (Expected results of chronic wound healing assessment and evolution), RESVECH 2.0 scale. The punctuation varies forn 0 to 35, with 6 subscales: Wound size, Depth/affected tissues, Borders, Type of tissue in the wound bed, Type of exudate and Infection/inflammation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Adult patients with chronic venous vascular ulcer located in lower limbs with signs of critical colonization, according to the criteria of Lazareth and Moore, which imply the presence of at least 3 of the following five:

  1. Severe pain during dressing change

  2. Perilesional edema.

  3. Local edema.

  4. Unpleasant smell.

  5. Abundant pus

  6. Microbial colonization higher than 100000 CFUs

Exclusion Criteria:
  • Patients younger than 18 years old.

  • Venous ulcer with signs of infection which requires antibiotic therapy

  • Venous ulcers that do not meet Lazareth and Moore criteria

  • Arterial ulcers.

  • Patients with type I or type II diabetes.

  • Patients with immunosuppression of any etiology or in immunosuppressive treatment or with NSAIDs.

  • Patients with rheumatoid arthritis in the acute phase.

  • Patients with dermatitis prior to the appearance of the ulcer.

  • Patients with neuropathy or lack of sensitivity of any etiology.

  • Patients who, for local or systemic clinical reasons, will need to initiate antibiotic therapy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Málaga Málaga Spain 29071

Sponsors and Collaborators

  • University of Malaga
  • BSN Medical GmbH
  • Andalusian Health Service

Investigators

  • Principal Investigator: José Miguel Morales Asencio, PhD, University of Malaga

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
JOSE MIGUEL MORALES ASENCIO, Head of the Department of Nursing. Professor of Research and Evidence Based Health Care, University of Malaga
ClinicalTrials.gov Identifier:
NCT03667937
Other Study ID Numbers:
  • CUCO-UV
First Posted:
Sep 12, 2018
Last Update Posted:
Mar 25, 2020
Last Verified:
Mar 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by JOSE MIGUEL MORALES ASENCIO, Head of the Department of Nursing. Professor of Research and Evidence Based Health Care, University of Malaga
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 25, 2020